Market Closed

ALDX
Aldeyra Therapeutics
$ 0.6438
2.17%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago

Aldeyra Therapeutics News

Latest Aldeyra Therapeutics Stock News & ALDX Headlines

Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally
2 months ago | benzinga.com
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
2 months ago | seekingalpha.com
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
2 months ago | marketbeat.com
Aldeyra Therapeutics to Host Regulatory Update Webcast
2 months ago | businesswire.com
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
5 months ago | gurufocus.com
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
5 months ago | businesswire.com
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
5 months ago | marketbeat.com
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
5 months ago | businesswire.com
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
6 months ago | newsfilecorp.com
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
6 months ago | gurufocus.com
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

ALDX
Aldeyra Therapeutics
$ 0.6438
2.17%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago